Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is developed as an Alzheimer's disease therapeutic.
|
$129.63M |
$2.15
+9.69%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$129.43M |
$0.38
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$127.95M |
$4.37
-0.23%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$127.80M |
$1.72
+2.69%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$125.54M |
N/A
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$124.61M |
$0.76
-1.85%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$124.59M |
$3.94
+4.93%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$119.56M |
$6.04
-2.58%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$118.59M |
$4.71
+2.95%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
|
LPTX
Leap Therapeutics, Inc.
Leap Therapeutics is a biotech company focused on oncology therapies, with lead assets in antibody-based cancer treatments.
|
$116.14M |
$2.04
+367.43%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$115.62M |
$1.95
-2.75%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$113.65M |
$36.38
-11.39%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$109.15M |
$1.74
+19.66%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$109.12M |
$2.54
+0.40%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$108.87M |
$3.36
-1.75%
|
|
MGNX
MacroGenics, Inc.
Pipeline includes antibody-drug conjugates (MGC026, MGC028, vobra duo) using a TOP1i payload.
|
$108.71M |
$1.72
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$106.43M |
$1.51
-1.31%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$105.77M |
$2.75
+1.10%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$103.68M |
$13.09
+11.40%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$103.60M |
$1.42
-1.05%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$103.60M |
$1.74
+0.29%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$103.60M |
$2.02
-2.18%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$101.84M |
$8.34
-0.24%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$100.62M |
$1.38
-1.08%
|
|
XTNT
Xtant Medical Holdings, Inc.
Xtant operates as an OEM/contract manufacturer for orthobiologic and implant products.
|
$97.35M |
$0.73
-6.45%
|
Showing page 16 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
